2016
DOI: 10.1016/j.cct.2016.09.003
|View full text |Cite
|
Sign up to set email alerts
|

Risk based monitoring (RBM) tools for clinical trials: A systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
33
0
2

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 38 publications
(40 citation statements)
references
References 14 publications
1
33
0
2
Order By: Relevance
“…[…] The sponsor may choose on-site monitoring, a combination of on-site and centralized monitoring, or, where justified, centralized monitoring". To date, only a few tools for implementing risk-based monitoring of clinical trials have been described [16,30,31], most of them combining on-site and centralized monitoring. Among them, risk-assessment tools were used within the French OPTIMON (for OPTImization of MONitoring -NCT00780091) trial [32] and the ADAMON (for ADApted MONitoring) projects.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[…] The sponsor may choose on-site monitoring, a combination of on-site and centralized monitoring, or, where justified, centralized monitoring". To date, only a few tools for implementing risk-based monitoring of clinical trials have been described [16,30,31], most of them combining on-site and centralized monitoring. Among them, risk-assessment tools were used within the French OPTIMON (for OPTImization of MONitoring -NCT00780091) trial [32] and the ADAMON (for ADApted MONitoring) projects.…”
Section: Discussionmentioning
confidence: 99%
“…However, considering the exponential rise in clinical research costs (SDV has been estimated to account for approximately 25% of overall clinical trial costs [3]) and the undemonstrated impact of full SDV on data quality [4][5][6][7][8], the question of implementing a reduced or a targeted SDV and its cost/benefit ratio has emerged [9][10][11][12]. Since the beginning of the decade, regulatory agencies have suggested that sponsors should adapt the nature and extent of the monitoring to a risk-based approach [13][14][15] and nowadays, there is a growing consensus that a monitoring focused on the most critical data elements and processes necessary to achieve study objectives is more interesting than routine visits to all clinical sites and 100% data verification to ensure overall study quality [16,17]. However, the impact of this approach on data quality needs to be evaluated.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Policies officially approved by a recognised government entity, whether peer-reviewed or not, were included in the study. e most commonly used quality assessment framework for grey literature is the Authority, Accuracy, Coverage, Objectivity, Date, Significance (AACODS) [29,92,93]. However, we found the AACODS framework inappropriate for the quality assessment of policy documents.…”
Section: Quality Assessmentmentioning
confidence: 90%
“…https://doi.org/10.1101/2020.04.01.20049627 doi: medRxiv preprint Dynamic methods risk-based monitoring scoping review -v1.0 29-Feb-2020.docx 6/47 including 'triggered monitoring' 14 or, as in ICH GCP guidance, 'targeted monitoring', 16 and may employ data-driven approaches from methods known collectively as 'central statistical monitoring', 17 or more subjective assessments. 14,18,19 A recent systematic review has established the breadth of tools available to assess overall trial risk (and to use this assessment to define the monitoring strategy) in the setup stage, 20 but so far there has been no such exercise for methods to assess ongoing site-level risk once a trial has started. We conducted a scoping review 21 to identify and characterise available methods.…”
Section: Summary Of Supplementary Information Introductionmentioning
confidence: 99%